Ligliptin activated the AMPK-SIRT1-PGC-1α pathway and inhibited the JAK2/STAT3 signaling pathway, downregulated TNF-α, IL-6 and NF-κB p65, and upregulated the anti-inflammatory cytokine IL-10, reducing the severity of colitis. Here, JAK2 is linked to colitis.